SCHEMBL974274

SCHEMBL974274

CN(C)CCNc1ccccc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 2/20 0.53
CYP2C19 P33261 2/20 0.47
SLC2A1 P11166 1/20 0.44
MALT1 Q9UDY8 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
HTT P42858 2/20 0.43
BRD4 O60885 1/20 0.42
ATAD2 Q6PL18 1/20 0.42
MAPT P10636 3/20 0.41
GAA P10253 3/20 0.41
ALPG P10696 1/20 0.41
SLC40A1 Q9NP59 1/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
POLB P06746 1/20 0.40
RAD52 P43351 1/20 0.40
KMT2A Q03164 2/20 0.40
TOP2A P11388 1/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30457115 1.00 NCF1 (0.53) NCF1CYP2C19SLC2A1MALT1HRH3
Hydrochloric Acid SCHEMBL9725413 0.98 NCF1 (0.51) NCF1CYP2C19SLC2A1MALT1HRH3
Hydrochloric Acid SCHEMBL9725565 0.98 NCF1 (0.51) NCF1CYP2C19SLC2A1MALT1HRH3
SCHEMBL30228008 0.89 POLB (0.47) NCF1SLC2A1BRD4ATAD2MAPT
SCHEMBL974271 0.89 POLB (0.47) NCF1SLC2A1BRD4ATAD2MAPT
SCHEMBL3870508 0.87 TOP2A (0.43) NCF1SLC2A1HRH3BRD4ATAD2
SCHEMBL3872395 0.86 HDAC3 (0.43) NCF1SLC2A1BRD4ATAD2POLB
SCHEMBL11749512 0.81 CHEK1 (0.54) CYP2C19HRH3HTTMAPTKDM4E
SCHEMBL16117778 0.81 BRD4 (0.47) NCF1CYP2C19SLC2A1HRH3HTT
SCHEMBL6201094 0.81 MAPT (0.52) CYP2C19HTTMAPTGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116178450-B O-phenylenediamine bridged bis-aryloxy single metallocene rare earth metal complex, preparation method and catalytic application thereof 苏州大学 2023-10-27 CN claimed
CN-116178450-A O-phenylenediamine bridged bis-aryloxy single metallocene rare earth metal complex, preparation method and catalytic application thereof 苏州大学 2023-05-30 CN claimed
EP-3976604-B1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2026-01-21 EP disclosed
CN-116178450-B O-phenylenediamine bridged bis-aryloxy single metallocene rare earth metal complex, preparation method and catalytic application thereof 苏州大学 2023-10-27 CN disclosed
CN-116178450-B O-phenylenediamine bridged bis-aryloxy single metallocene rare earth metal complex, preparation method and catalytic application thereof 苏州大学 2023-10-27 CN disclosed
CN-116178450-A O-phenylenediamine bridged bis-aryloxy single metallocene rare earth metal complex, preparation method and catalytic application thereof 苏州大学 2023-05-30 CN disclosed
CN-116178450-A O-phenylenediamine bridged bis-aryloxy single metallocene rare earth metal complex, preparation method and catalytic application thereof 苏州大学 2023-05-30 CN disclosed
US-20230092890-A1 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) 2023-03-23 US disclosed
EP-3976604-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2022-04-06 EP disclosed
WO-2020240492-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2020-12-03 WO disclosed
EP-2178861-B1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS MERCK SHARP & DOHME (US) 2014-08-20 EP disclosed
US-20030236282-A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) 2003-12-25 US disclosed
US-6204264-B1 Benzimidazole derivative, hair growth promoter and external composition for skin using the same SHISEIDO CO., LTD. (JP) 2001-03-20 US disclosed
EP-0989123-A1 Benzimidazole derivative, hair growth promoter and external composition for skin using the same SHISEIDO COMPANY LIMITED (JP) 2000-03-29 EP disclosed
EP-0238459-B1 SUBSTITUTED INDOLOQUINOXALINES Lundblad, Leif (SE) 1992-04-15 EP disclosed
US-4990510-A Viricides, anticancer agents LEIF LUNDBLAD (BE) 1991-02-05 US disclosed
EP-0238459-A1 Substituted indoloquinoxalines Lundblad, Leif (SE) 1987-09-23 EP disclosed
WO-1987004436-A1 SUBSTITUTED INDOLOQUINOXALINES LUNDBLAD, LEIF (SE) 1987-07-30 WO disclosed
US-4058529-A Polycyclic amino derivatives of pyrrolidone and piperidone CIBA-GEIGY CORPORATION (US) 1977-11-15 US disclosed
US-4053472-A MICROBIOCIDES SCHERING AKTIENGESELLSCHAFT (DT) 1977-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092890-A1 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same HDAC6, HDAC1, HDAC2 NCF1 1778/4885CYP2C19 597/4885SLC2A1 4241/4885
US-20030236282-A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof P2RX5, CALCRL, ADRA1D NCF1 1849/4885CYP2C19 983/4885SLC2A1 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.